Topical Gentamicin Nonsense Suppression Therapy of EB

NCT ID: NCT04644627

Last Updated: 2022-05-03

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE1/PHASE2
• Total Enrollment: 4 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2020-12-01
• Study Completion Date: 2022-05-01

Brief Summary

The overall purpose of this study is to address whether topical gentamicin therapy is an effective and feasible treatment. Specifically, we will investigate the effect of non-intensive treatment (once daily or every other day) on skin protein expression, as well as quantify the effect on wound healing in patients with EB caused by PSC (part A). Furthermore, we will address in vitro whether gentamicin restores protein expression of genes affected by SSM in fibroblasts derived from skin biopsies obtained from patients with EB caused by SSM (part B). If these in vitro experiments yield positive results, the patients donating the cells will be offered to enter part A of this study. The overall duration of part A in this study is planned to be 18 weeks per patients and consists of a 6 weeks treatment period followed by a 12 week follow up period. Each patient will attend 3 study visits: at week 0, week 6 and week 18. All patients will be included within a time period of 12 months. The overall duration of part B will be up to 8 weeks per patients of which 4-7 weeks are spent to prepare fibroblasts obtained from skin biopsies. Then 5 days of in vitro intervention and subsequent analysis follows. Altogether, the duration of the GENTELBULL study will be 78 weeks or less.

Conditions

Epidermolysis Bullosa

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Single arm

Each patient serves as its own control: one half is treated with the study treatment in addition to standard wound therapy, the other half receives standard wound therapy only.

Group Type: EXPERIMENTAL

Gentamicin Sulfate

Intervention Type: DRUG

Topical gentamicin ointment on wounds once daily for 6 weeks

Interventions

Gentamicin Sulfate

Topical gentamicin ointment on wounds once daily for 6 weeks

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

1. The patient has EB caused by nonsense mutation

2. The patient has a symmetrical distribution of wounds which allows for wounds on one side of the body to serve as control wounds, while study therapy is applied to the other side.

3. The patient (if an adult) or parent(s)/guardian(s) is capable of giving signed informed consent as described in Appendix 1 which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in this protocol.

4. Women of childbearing potential must use a highly effective contraception method

Exclusion Criteria

1. Known contact allergy against gentamicin sulfate or other ingredients in the ointment

2. Known intolerance to gentamicin sulfate of any sort

3. Moderate or severely reduced kidney function (eGFR <45)

4. Use other experimental therapy against EB

5. Receiving systemic aminoglycosides during the last 3 months

6. The patient uses muscle relaxant drug(s)

• Eligible Sex: ALL
• Accepts Healthy Volunteers: Yes

Sponsors

Oslo University Hospital

OTHER

Sponsor Role: lead

Responsible Party

Øystein Sandanger

Principal Investigator

Responsibility Role: PRINCIPAL_INVESTIGATOR

Principal Investigators

Øystein Sandanger, MD, PhD

Role: PRINCIPAL_INVESTIGATOR

Section of Dermatology, OUS

Locations

Oslo University Hospital

Oslo, , Norway

Countries

Norway

Other Identifiers

105989

Identifier Type: -

Identifier Source: org_study_id